1509928-04-4

1509928-04-4 structure

1509928-04-4 structure

Name: Istiratumab
Chemical Name: Istiratumab
CAS Number: 1509928-04-4
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways JAK/STAT Signaling EGFR
Create Date: 2023-03-11 17:48:38
Modify Date: 2024-04-03 17:27:38
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].

Name	Istiratumab

Description	Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> IGF-1R
In Vitro	Istiratumab (500 nM，24 小时) 在人胰腺癌细胞系中抑制 IGF-1 和 HRG 共刺激引起的AKT 激活[2]。 Istiratumab (500 nM，24 小时) 抑制具有激活 KRAS 突变的胰腺癌细胞中 IGF-1 和 HRG 诱导的 AKT 磷酸化[2]。 Istiratumab (500 nM, 24 h) 通过蛋白酶体途径诱导 IGF-1R 和 ErbB3 受体降解[2]。 Istiratumab (1 μM，60 分钟) 阻断卵巢癌细胞系中 PI3K 和 MAPK 信号级联的激活[3]。 Western Blot Analysis[2] Cell Line: AsPC1, BxPC3, Capan2, CFPAC1, etc. Concentration: 500 nM Incubation Time: 24 h Result: Decreased IGF-1R and/or ErbB3 protein levels in pancreatic cancer cell lines.
References	[1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. [2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. [3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832.

No Any Chemical & Physical Properties